HCW Biologics HCWB Stock
HCW Biologics Price Chart
HCW Biologics HCWB Financial and Trading Overview
| HCW Biologics stock price | 4.5 USD |
| Previous Close | 4.42 USD |
| Open | 4.44 USD |
| Bid | 3.17 USD x 200 |
| Ask | 5.58 USD x 200 |
| Day's Range | 4.31 - 4.51 USD |
| 52 Week Range | 1.5 - 44.1 USD |
| Volume | 19.31K USD |
| Avg. Volume | 2.18M USD |
| Market Cap | 7.19M USD |
| Beta (5Y Monthly) | 2.302 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -49.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30 USD |
HCWB Valuation Measures
| Enterprise Value | 10.31M USD |
| Trailing P/E | N/A |
| Forward P/E | -8.181818 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.0900542 |
| Price/Book (mrq) | 0.87650955 |
| Enterprise Value/Revenue | 1.564 |
| Enterprise Value/EBITDA | -1.81 |
Trading Information
HCW Biologics Stock Price History
| Beta (5Y Monthly) | 2.302 |
| 52-Week Change | -83.10% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 44.1 USD |
| 52 Week Low | 1.5 USD |
| 50-Day Moving Average | 6.87 USD |
| 200-Day Moving Average | 9.55 USD |
HCWB Share Statistics
| Avg. Volume (3 month) | 2.18M USD |
| Avg. Daily Volume (10-Days) | 60.57K USD |
| Shares Outstanding | 1.6M |
| Float | 975.08K |
| Short Ratio | 0.21 |
| % Held by Insiders | 9.24% |
| % Held by Institutions | 8.59% |
| Shares Short | 41.71K |
| Short % of Float | 2.77% |
| Short % of Shares Outstanding | 2.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -34.74% |
| Operating Margin (ttm) | 49.45% |
| Gross Margin | 99.23% |
| EBITDA Margin | -86.40% |
Management Effectiveness
| Return on Assets (ttm) | -15.060% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 6.59M USD |
| Revenue Per Share (ttm) | 12.46 USD |
| Quarterly Revenue Growth (yoy) | 129080.69% |
| Gross Profit (ttm) | 6.54M USD |
| EBITDA | -5696189 USD |
| Net Income Avi to Common (ttm) | -18117820 USD |
| Diluted EPS (ttm) | -49.74 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.23M USD |
| Total Cash Per Share (mrq) | 1.1 USD |
| Total Debt (mrq) | 6.58M USD |
| Total Debt/Equity (mrq) | 114.14 USD |
| Current Ratio (mrq) | 0.086 |
| Book Value Per Share (mrq) | 5.134 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11452987 USD |
| Levered Free Cash Flow (ttm) | -10438363 USD |
Profile of HCW Biologics
| Country | United States |
| State | FL |
| City | Miramar |
| Address | 2929 North Commerce Parkway |
| ZIP | 33025 |
| Phone | 954 842 2024 |
| Website | https://www.hcwbiologics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Q&A For HCW Biologics Stock
What is a current HCWB stock price?
HCW Biologics HCWB stock price today per share is 4.5 USD.
How to purchase HCW Biologics stock?
You can buy HCWB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HCW Biologics?
The stock symbol or ticker of HCW Biologics is HCWB.
Which industry does the HCW Biologics company belong to?
The HCW Biologics industry is Biotechnology.
How many shares does HCW Biologics have in circulation?
The max supply of HCW Biologics shares is 1.6M.
What is HCW Biologics Price to Earnings Ratio (PE Ratio)?
HCW Biologics PE Ratio is now.
What was HCW Biologics earnings per share over the trailing 12 months (TTM)?
HCW Biologics EPS is -49.74 USD over the trailing 12 months.
Which sector does the HCW Biologics company belong to?
The HCW Biologics sector is Healthcare.
HCW Biologics HCWB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26107.01 USD — |
+0.9
|
6.19B USD — | 25912.4 USD — | 26168.81 USD — | — - | 6.19B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2300.52 USD — |
+1.08
|
— — | 2282.75 USD — | 2307.4 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1241.24 USD — |
-1.09
|
— — | 1237.77 USD — | 1248.69 USD — | — - | — — |
- {{ link.label }} {{link}}